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Abstract
We discuss a case of a 67 year old woman presented to the Emergency Department of the Gold Coast Hospital
(Queensland, Australia) in February 2008 with a one hour history of central heavy chest pain with radiation to
her left arm.
Case Report
A 67 year old woman presented to the Emergency Department of  the Gold Coast  Hospital  (Queensland,
Australia) in February 2008 with a one hour history of central heavy chest pain with radiation to her left arm.
She denied any other associated symptoms and her pain was relieved with sublingual glyceryl trinitrate in
addition  to  intravenous  morphine.  She  was  also  prescribed  300  milligrams  of  aspirin  as  per  chest  pain
protocol. Initially her blood pressure was stable and recorded as 121/82. She was not tachycardiac and the
remainder of her vital signs within normal limits. Her physical examination was unremarkable. During her stay
in the emergency department her blood pressure dropped to 71/34 and an electrocardiogram (ECG) revealed
an inferior ST segment elevation.
The patient’s cardiac risk factors included a history of hypertension and a previous non-ST segment elevation
myocardial infarction (NSTEMI) which required stenting to the right coronary artery (RCA) on the 18th of June
2003 with a Cypher® drug eluting stent (DES). The patient had been on clopidogrel antiplatelet therapy since
her initial angiogram however had ceased this 6 days prior to presentation in line with surgical advice prior to
an expected colonoscopy. It was unknown as to why she was continuing to receive clopidogrel therapy and
why she was not on dual antiplatelet therapy.
Following the acquisition of the ECG the patient was subsequently transferred to the coronary catheter lab for
primary  percutaneous  coronary  intervention  (PCI).  Coronary  catheterisation  revealed  a  normal  left  main
coronary artery (LMCA), some minor irregularities in the left anterior descending (LAD), minor disease in the
circumflex artery but of greatest importance was
Following acquisition of the ECG, the patient was transferred to the coronary catheter lab for primary PCI. This
showed normal LMCA, minor irregularities in the LAD, minor disease in the circumflex but most importantly
occlusion  in  a  previously  stented  region  in  the  RCA.  The  lesion  was  balloon-angioplastied  without  the
requirement for further stenting. Angiographically a good result was obtained with no residual stenosis. The
troponin I (cTnI) peaked at 3.4 micrograms per litre (normal range is less than 0.04 micrograms per litre).
She had an uneventful  recovery and a routine echocardiogram was performed following her angiography
which showed preserved left ventricular systolic function. She was subsequently discharged on day 2 following
her angioplasty.
Discussion
Late stent thrombosis is a well known complication of drug eluting stents (DES) following revascularisation
during coronary angiography. A meta-analysis of over 6000 patients by Bavry et al.,  2006, incorporating
randomised controlled trials of paclitaxel stents versus bare metal stents (BMS) or sirolimus stents versus
bare metal stents (BMS) indicated that the risk of late thrombosis is increased 4-5 fold in drug eluting stents
after 6-12 months following revascularisation. In the analysis provided, the incidence of early thrombosis
between DES and BMS was similar up to 1 month, beyond which there was a greater risk with DES1. The
median time to thrombosis observed through the study for sirolimus and paclitaxel stents respectively were
15.5 and 18 months, 11 and 14 months longer than late BMS thrombosis1. What still remains unclear is how
long after revascularisation can thrombosis occur and currently there have been limited reports beyond 1 year
of implantation.
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The term very late stent thrombosis has been used loosely without adequate definition. The implications of
such relate to the duration of anti-platelet therapy required and the time period over which this continues to
be instituted. The time period of occurrence of very late stent thrombosis (VLST) is ill defined with 12 months
post implantation as the current marker2. The number of reported very late stenoses is limited, likely due to
the limited follow up of coronary stent patients. Currently the longest reported case is 834 days following
implantation reported by Merkely et al., 2009. We present here a case of VLST occurring almost 6 years after
insertion of a sirolimus drug eluting stent in a patient on clopidogrel.
As  noted  by  many  authors  restenosis  in  a  drug  eluting  stent  beyond  1  year  of  implantation  is  a  rare
occurrence with reports from Henderson et al., 2006 and Luscher et al., 2007 suggesting the occurrence of
VLST after implantation of a DES at 4 years (comparing pooled data) is 0.6% to 0.7%4,5. Lagerqvist et al.,
2007 also reported an increased rate of death, as compared to bare-metal stents in a Swedish retrospective
study. The trend indicted that the risk of death was 0.5 percentage points higher and composite death or MI
was 0.5 to 1.0 percentage points higher per year after 6 months6. This brought into question the long term
safety of drug-eluting stents and called for randomised trials to evaluate the risk. A follow on study by James
et  al.,  2009 analysing  patients  from the  same registry  (Swedish  Coronary  Angiography  and  Angioplasty
Registry) dispelled any suggestion of a significant difference in the combined outcome of death and MI in
those receiving DES or BMS. This study also reinforced the risk of late events, with significantly higher rates of
late events in those receiving DES as compared with those receiving BMS7.
A great area of controversy which still remains is the length of treatment for antiplatelet therapy. Current
guidelines  by  the  American  College  of  Cardiologists  (ACC)  and  American  Heart  Association  (AHA)  joint
taskforce suggest than in patients who have undergone PCI, clopidogrel 75 milligrams daily should be given
for at least 3 months after sirolimus stent implantation, and 6 months after paclitaxel stent implantation, and
ideally up to 12 months in patients who are not at high risk of bleeding8. Furthermore following restenosis,
the guidelines advise indefinite use of antiplatelet therapy.
In the case presented the restenosis occurred 2110 days following the implantation of the stent, triggered 6
days after cessation of clopidogrel. Some suggestions for potential causes of late stent thrombosis include
delayed healing which is consistent with reported high rates of death and myocardial infarction in patients
with drug eluting stents after cessation of clopidogrel, from the Duke database. The study indicated that
among patients who had a DES who were event free at 6 months, clopidogrel use was a statistical significant
predictor of lower adjusted rates of death (2.0% with clopidogrel compared with 5.3% without) and death or
MI (3.1% vs. 7.2%) at 24 months. Among patients with DES who were event-free at 12 months (252 with
and 276 without clopidogrel), clopidogrel use continued to predict statistically significant lower rates of death
(0% vs. 3.5% without clopidogrel use) and death or myocardial infarction (MI) (0% vs. 4.5% without) at 24
months9.  The  study  concluded  that  indeed  long  term  use  of  clopidogrel  in  patients  with  DES  may  be
associated with a reduced risk for death and death or MI. The issue which still remains is what the appropriate
duration of Clopidogrel therapy should be and what the temporal relationship between Clopidogrel cessation
and VLST is.
A single centre observational study was conducted by Roy et al., 2009 which assessed compliance to dual
antiplatelet therapy particularly clopidogrel following implantation of DES and subsequent angiographic or
autopsy-proven stent occlusion. The investigators concluded that clopidogrel cessation was an independent
predictor of cumulative stent thrombosis at 30 days and 6 months but not at 12 months10.
Often patient factors may contribute to increased risk of stenosis, such as diabetes or tortuous coronary
anatomy as  well  as  complex  lesions,  in  which case  DES are  often  indicated.  In  the  case  presented,  no
comorbidities  were  present  and  restenosis  occurred  some  5  years  and  9  months  following  implantation
indicating that there are no definitive factors which predict very long term outcomes of stent implantation.
However of interest was the lack of dual antiplatelet therapy. Dean et al., 2009 found that prolonged dual
antiplatelet  therapy improves clinical  outcomes in patients considered high risk  who have had Sirolimus-
eluting stents implanted. At 12 and 18 months followed, the investigators showed that those patients who had
taken standard clopidogrel therapy with aspirin (i.e. 12 months) had an increased risk of VLST compared with
those on prolonged clopidorgel therapy (18 months) and aspirin (5.6% vs. 1.1%)11. The case we reported did
not represent a high risk patient however, as she had no significant comorbidities. The mechanism of VLST is
thus still uncertain. Some have postulated that poor endothelialisation with ongoing clopidogrel therapy may
have a role in the mechanism. Could the stent thrombosis be related to the lack of aspirin management. What
is clear from this case and any further VLST cases which may be reported, is that there may be a necessity to
alter current guidelines for antiplatelet therapy. It is evident that although guidelines exist, this is what they
are  and  that  therapy  should  be  tailored  to  each  individual,  and  issues  such  as  risk  benefit  need  to  be
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considered  when  contemplating  duration  of  antiplatelet  therapy.  Ultimately  there  is  need for  large  scale
randomised clinical trials for the evaluation of duration of antiplatelet therapy.
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